Publications by authors named "Jin H Kang"

Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021-2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy ( = 33), HSCT ( = 27), and healthy controls ( = 20).

View Article and Find Full Text PDF

Clinicians have recognized the similarities and differences between the two subtypes of common epidermal growth factor receptor (EGFR) mutations, but actual treatment strategies have not yet changed. The L858R mutation can be understood by considering the pharmacological conformational plasticity of the receptor protein and the presence of other co-occurring mutations, whether subtypes of EGFR or non-EGFR mutations and differences in downstream signaling pathways. As long as we know that molecular differences lead to biological differences, it is a challenge for all of us that our treatment strategies must change.

View Article and Find Full Text PDF
Article Synopsis
  • EGFR-variant non-small cell lung cancer (NSCLC) is prone to central nervous system (CNS) metastases, making new treatment options like lazertinib important for improving patient outcomes.
  • This study was a phase 2 trial in South Korea involving patients with NSCLC and existing brain metastases who had not responded to first or second-generation EGFR inhibitors, assessing lazertinib's effectiveness.
  • Results showed a 55% intracranial objective response rate (iORR) for patients, with higher responses in those with specific genetic markers, indicating that lazertinib could be a promising option for treating CNS metastases in these patients.
View Article and Find Full Text PDF

Macrophage activation syndrome (MAS) is potentially fatal; so, early diagnosis and timely treatment are essential. However, detecting MAS is sometimes challenging because its principal features can be observed in other pediatric diseases that cause severe inflammation. Cytokine storm due to immune dysregulation represents the clinical and laboratory features of MAS that are included in the diagnostic criteria.

View Article and Find Full Text PDF

Background: Apolipoprotein B mRNA editing catalytic polypeptide (APOBEC), an endogenous mutator, induces DNA damage and activates the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway. Although cisplatin-based therapy is the mainstay for muscle-invasive bladder cancer (MIBC), it has a poor survival rate. Therefore, this study aimed to evaluate the efficacy of an ATR inhibitor combined with cisplatin in the treatment of APOBEC catalytic subunit 3B (APOBEC3B) expressing MIBC.

View Article and Find Full Text PDF

Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies.

View Article and Find Full Text PDF

Universal varicella vaccination (UVV), as a single dose to children aged 12 to 15 months, was introduced in Korea in 2005. A seroprevalence study is required to upgrade this UVV strategy. The fluorescent antibody to membrane antigen (FAMA) assay is the gold standard for varicella-zoster virus (VZV) immunity testing.

View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib, a targeted therapy for EGFR-mutated lung cancer, demonstrated better progression-free survival compared to gefitinib in patients with central nervous system (CNS) metastases in the LASER301 study.
  • The study included treatment-naive patients with advanced NSCLC who were randomized to receive either lazertinib or gefitinib, with regular CNS imaging to assess treatment effects.
  • Results showed that patients treated with lazertinib had a median intracranial progression-free survival of 28.2 months, significantly longer than the 8.4 months for those treated with gefitinib, indicating lazertinib's effectiveness in managing CNS metastases.
View Article and Find Full Text PDF
Article Synopsis
  • Live varicella vaccines usually protect kids from chickenpox and shingles, but sometimes the vaccine can cause a rash instead.
  • A child got very sick and sadly died after getting a booster shot of a vaccine that had a new strain of the virus called OKA/SK.
  • This case showed that we need to be careful with vaccines and find ways to keep kids safe from serious side effects.
View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib is a new targeted therapy for non-small cell lung cancer (NSCLC) that has shown better efficacy than gefitinib in a study focused on Asian patients with specific EGFR mutations.
  • The LASER301 phase 3 study found that patients receiving lazertinib had a significantly longer progression-free survival (20.6 months) compared to those on gefitinib (9.7 months).
  • Both medications had similar safety profiles, with only slight differences in adverse events leading to discontinuation, making lazertinib a promising option for treating these patients.
View Article and Find Full Text PDF

Introduction: This study aimed to assess the role of adenosine triphosphate (ATP) bioluminescence level monitoring for identifying reservoirs of the outbreak pathogen during two consecutive outbreaks caused by Enterococcus faecium and Staphylococcus capitis at a neonatal intensive care unit (NICU). The secondary aim was to evaluate the long-term sustainability of the infection control measures employed one year after the final intervention measures.

Methods: Two outbreaks occurred during a 53-day period in two disconnected subunits, A and B, that share the same attending physicians.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed the effectiveness and safety of lazertinib compared to gefitinib in treating Korean patients with EGFR-mutated non-small cell lung cancer (NSCLC) as part of the phase 3 LASER301 trial.
  • A total of 172 patients were randomized to receive either lazertinib (240 mg/day) or gefitinib (250 mg/day), with the main goal of assessing progression-free survival (PFS).
  • Results showed that lazertinib significantly improved median PFS (20.8 months) compared to gefitinib (9.6 months) and had a similar safety profile, suggesting lazertinib could be a promising new treatment option for these patients.
View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib, a third-generation EGFR tyrosine kinase inhibitor, was tested in a global phase III study (LASER301) against gefitinib for treating patients with advanced non-small-cell lung cancer (NSCLC) who had specific EGFR mutations.
  • The study included 393 treatment-naïve patients and found that those taking lazertinib had a significantly longer median progression-free survival (20.6 months) compared to gefitinib (9.7 months), with similar overall response rates for both treatments.
  • Ultimately, lazertinib showed improved efficacy over gefitinib in managing advanced NSCLC, while maintaining a safety profile consistent with previous findings.
View Article and Find Full Text PDF
Article Synopsis
  • Increased interest in all-solid-state batteries is driven by their safety and durability, thanks to solid electrolytes that are less flammable and mechanically stronger than liquid options.
  • A major challenge is the low lithium-ion conductivity of solid electrolytes, impacted by how well Li ions diffuse through the material and the contact area between particles, influenced by their size and shape.
  • This study investigates how pressurization affects electrolyte conductivity, finding that the conductivity scales with pressure differently depending on whether bulk or grain boundary conductivity is dominant, which could help identify the best performing electrolyte materials.
View Article and Find Full Text PDF

Lanza, MB, Jin, KH, Karl, H, Myers, J, Ryan, E, and Gray, VL. Hip abductor power and velocity: reliability and association with physical function. J Strength Cond Res 37(2): 284-290, 2023-Muscle power, defined as the ability of the muscle to produce torque quickly, has received little attention and may be critical for understanding physical function and performance.

View Article and Find Full Text PDF

In the last few decades, macrolide-resistant Mycoplasma pneumoniae (MRMP) has been increasing in proportion. This study aimed to evaluate the treatment outcomes of children with lobar or segmental MP pneumonia unresponsive to the initial 3−5-day macrolide therapy, who then switched to either a non-macrolide, macrolide + steroid, or a non-macrolide + steroid regimen, according to the 2019 KSPID and KAPARD guideline during the 2019−2020 Mycoplasma epidemic in South Korea. A total of 190 patients <18 years old were admitted during the study period for MP lobar or segmental pneumonia, and 16.

View Article and Find Full Text PDF

Objectives: The pathologic nodal stage of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) patients is classified according to the number of lymph nodes (LNs), as revised in 2018. Previous studies showed that the LN ratio (LNR) could be also a significant prognostic factor in head and neck cancer, but there are few studies on the LNR in HPV-related [HPV(+)] OPC. The aim of the present study was to analyze the predictive value of the LNR for survival and recurrence in HPV(+) OPC patients.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with mutation-positive non-small cell lung cancer treated with first-line afatinib inevitably develop resistance, making access to effective second-line treatments crucial for managing disease progression.
  • In a study of 737 patients, those who received subsequent osimertinib after acquiring the T790M mutation showed a longer total time on treatment (35.10 months) compared to those who didn't have the mutation and received chemotherapy (18.80 months) or had unknown mutation status (12.00 months).
  • The results indicated a high overall response rate (75.7%) for afatinib and notable CNS efficacy, with 67.0% response rate in patients with initial brain metastasis, suggesting that sequential treatment could
View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs) offer improved survival for patients with advanced malignant melanomas. However, only a subset of these patients exhibit an objective response rate of 10-40 % with ICIs. We aimed to ascertain the effects of RNA signatures and the spatial distribution of immune cells on the treatment outcomes of patients with malignant melanomas undergoing ICI therapy.

View Article and Find Full Text PDF

Purpose: Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and cost-effectiveness are a concern, prompting the need for tools to facilitate value assessment of therapeutics. This study reviews the value assessment tools, and evaluates the value of emerging therapeutics in RCC.

View Article and Find Full Text PDF

Introduction: Although prolonged fever in patients with neutropenic fever (NF) during empirical antibiotic therapy could be caused by dysregulated immune responses, its association with cytokine concentrations has rarely been investigated. This study determined the kinetics of cytokine concentrations in pediatric patients with NF and bacteremia and evaluated the impact of cytokine concentration kinetics on prolonged fever.

Methods: Concentrations of 13 cytokines were measured on the initial day of NF (Day 1) and 3 days (Day 4) and 7 days (Day 8) later in 10 patients with NF with bacteremia, and their kinetics was determined.

View Article and Find Full Text PDF

Background: Data on whether physical activity (PA) levels are related to nonalcoholic fatty liver disease (NAFLD) when considering body mass index (BMI) are scarce. We assessed whether PA affects the development or resolution of NAFLD in conjunction with BMI changes.

Methods: Overall, 130,144 participants who underwent health screening during 2011-2016 were enrolled.

View Article and Find Full Text PDF